Objective: To study whether the temporal pattern of transient hyponatremia development in acute heart failure might provide insight into its pathophysiology and prognostic relevance.
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Transient Hyponatremia during Hospitalization for Acute Heart Failure
Clinical research study Conclusions: Transient hyponatremia is prognostically relevant, but has a heterogeneous etiology according to its temporal pattern of development.
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INTRODUCTION
Hyponatremia, defined as a serum sodium level <135 mmol/L, is common in heart failure. It is present in ~20% of patients admitted with acute heart failure and develops during decongestive treatment in an additional ~15-25% [1, 2, 3] .
Hyponatremia in heart failure is associated with worse outcomes and increased mortality, especially when persistent [4, 5] . However, it remains unclear whether this relationship is causal or if hyponatremia just represents a marker of more advanced disease. Studies assessing the prognostic impact of correcting hyponatremia during decongestive treatment in acute heart failure have yielded conflicting results [6, 7] . This should not be surprising as the underlying pathophysiological mechanisms of hyponatremia in heart failure are complex and diverse, warranting an individualized approach [8] . The temporal pattern of hyponatremia development might help to assess its etiology and could portend prognostic significance. The aim of the current analysis was to characterize two distinct patterns of transient hyponatremia development in patients with acute heart failure undergoing decongestive treatment: (1) decompensation hyponatremia, present upon admission but disappearing with decongestive treatment versus (2) treatment-induced hyponatremia, not present at admission but developed during decongestive treatment and present at discharge. Baseline and treatment characteristics as well as prognostic significance of those patterns were compared with both persistent and no hyponatremia development in patient populations from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization
Effectiveness (ESCAPE) and Diuretic Optimization Strategies Evaluation in Acute Heart
Failure (DOSE AHF) study.
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MATERIAL AND METHODS
Study design
This study is a post-hoc analysis from the ESCAPE and DOSE AHF study.
Detailed methods of those studies have been reported elsewhere [9, 10] . For the purpose of the current analysis, patients were selected who had serum sodium levels available at baseline and at least at one other moment during their index hospitalization.
Patients not discharged alive were excluded. All-cause mortality, orthotopic heart transplantation, left ventricular assist device implantation, and heart failure readmissions were adjudicated end-points in both trials.
Hyponatremia patterns
Persistent hyponatremia was defined as hyponatremia (i.e., serum sodium levels <135 mmol/L) present on admission and persisting till discharge. Decompensation hyponatremia was specified as admission hyponatremia that disappeared with decongestive treatment at discharge. Treatment-induced hyponatremia was defined by normal admission serum sodium levels (i.e., ≥135 mmol/L) with a subsequent drop <135 mmol/L at discharge. Baseline and treatment characteristics were compared according to the pattern of hyponatremia development. Plasma N-terminal of the prohormone of B-type natriuretic peptide (NT-proBNP) levels, plasma renin activity and plasma aldosterone levels were assessed only in DOSE AHF patients with a full set of biomarkers available at baseline and after 72 h (n=308). For the same group, diuretic efficacy was defined as net fluid balance after 72 h per 40 mg of furosemide-equivalent dose administered. Net fluid balance was not consistently reported in the ESCAPE.
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Study end-points
The primary end-point for this analysis was all-cause mortality. The secondary end-point constituted the combination of all-cause mortality or unscheduled heart failure hospitalization. Data were censored in case of orthotopic heart transplantation or implantation of a left ventricular assist device or at the end of follow-up after 180 days in the ESCAPE and 60 days in the DOSE AHF study.
Statistical analysis
Continuous variables are expressed as mean ± standard deviation if normally distributed or otherwise as median (interquartile range) and compared using the with corresponding 95% confidence interval (95% CI) for occurrence of the primary and secondary study end-points associated with each pattern of hyponatremia development.
Statistical significance was always set at a 2-tailed probability level of <0.05. All statistics were performed using IBM® SPSS® (version 22.0 for Windows). All authors had full access to the data and contributed to the writing of the manuscript. Together, they take responsibility for the integrity of the data and agree to the report as written.
RESULTS
Study population characteristics
A study flowchart is presented in Figure 1 . Seven hundred sixteen patients from the original ESCAPE and DOSE AHF studies (97%) were included in the current analysis. Their baseline characteristics are presented in Table 1 . Twenty percent of patients presented with hyponatremia upon admission, with another 17% developing it during decongestive treatment. Hyponatremia occurred more frequently in the ESCAPE (23% and 21% for admission and treatment-induced hyponatremia, respectively) compared to the DOSE AHF study (15% and 12%, respectively). Development of hyponatremia at any time-point was associated with a lower left ventricular ejection fraction (Table 1) . Persistent and decompensation but not treatment-induced hyponatremia patients demonstrated significantly elevated blood urea nitrogen (BUN) at baseline, despite similar serum creatinine levels compared to patients without hyponatremia (Table 1) . In addition, patients with persistent compared to no hyponatremia also had significantly lower arterial blood pressure, with values in patients with decompensation or treatment-induced hyponatremia situated in between (Table 1) .
Decongestive treatment strategy and hyponatremia patterns
None of the patterns of hyponatremia development were more common with either a strategy of continuous versus bolus or high-dose versus low-dose loop diuretics in the DOSE AHF study. There was also no association between hyponatremia development and randomization to pulmonary artery catheter-guided therapy versus 
Effective decongestion and hyponatremia patterns in the ESCAPE and DOSE AHF study
In the DOSE AHF study, baseline levels of plasma NT-proBNP were not different at 4,435 ng/L (2,446-9,907 ng/L) regardless of the pattern of hyponatremia development (P-value=0.359; Table 2 ). Figure 2 shows the relative change in plasma NT-proBNP levels after decongestive treatment at discharge, which was significantly different according to the pattern of hyponatremia development (P-value=0.010). While patients
with treatment-induced hyponatremia had a similar decrease in plasma NT-proBNP levels at discharge compared to patients without hyponatremia, this decrease was significantly less pronounced in patients with persistent hyponatremia and reversible decompensation hyponatremia (Table 2) . Among 172 patients from the ESCAPE randomized to pulmonary artery catheter use, central venous pressure at discharge was 8 ± 4 mmHg in patients without hyponatremia, which was not different in patients with treatment-induced hyponatremia (9 ± 6 mmHg; P-value=0.792), but lower compared to patients with persistent or reversible decompensation hyponatremia (both 11 ± 6 mmHg; P-value=0.019). Table 2 also displays the baseline and discharge values for plasma renin activity and plasma aldosterone levels in the DOSE AHF study. The baseline levels of plasma renin activity, obtained before randomization, but often after the first administration of loop diuretics, were markedly elevated in patients with persistent hyponatremia (P-value<0.001), intermediate in patients with decompensation hyponatremia (P-value=0.002), but not different in patient with treatment-induced hyponatremia (P-value=0.073) compared to patients without hyponatremia. After decongestive treatment however, the relative increase in plasma renin activity was the highest in the latter group. As a result, only patients with persistent (P-value<0.001) and treatment-induced hyponatremia (P-value=0.014) but not reversible decompensation hyponatremia (P-value=0.584) had significantly higher levels at discharge compared to patients without hyponatremia.
Neurohumoral activation and hyponatremia patterns in the DOSE AHF study
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Hyponatremia patterns and clinical outcome
During follow-up, 96 patients died (13%) and 239 were readmitted for heart failure (33%). Fourteen patients underwent placement of a left ventricular assist device and were censored at that time-point, with 6 of these patients subsequently undergoing orthotopic heart transplantation. Twenty-seven other patients were censored because of orthotopic heart transplantation. Only 19 patients (3%) were censored because of loss to follow-up before the end of the study. Both the risk for all-cause mortality ( Figure 3 ) and the risk for death or heart failure readmission ( Figure 4 ) were significantly associated with the pattern of hyponatremia development that was observed. Patients who demonstrated persistent hyponatremia had the highest risk for both end-points (Table 3 ).
The risk for adverse clinical outcome with reversible decompensation hyponatremia and treatment-induced hyponatremia was intermediate, while those without any hyponatremia had the lowest risk ( Figure 3, 4) . poor diuretic efficacy and marked neurohumoral activation during treatment, suggesting that decongestive therapy was overly aggressive. Treatment-induced hyponatremia was common with an incidence of 17% and associated with a significant 43% relative risk increase for death or heart failure readmission.
DISCUSSION
Studies have consistently reported that persistent hyponatremia in heart failure characterizes a population that has more advanced disease, with more pronounced neurohumoral activation, and higher risk of adverse clinical outcomes, which is corroborated by the current analysis [6, 11, 12] . As the DOSE AHF data uniquely provide prospectively collected plasma renin activity and plasma aldosterone levels at baseline and discharge, it was shown that persistent hyponatremia in acute heart failure was associated with exceedingly high plasma renin activity levels during decongestive treatment, even in the contemporary area of neurohumoral blocker treatment. This was further supported by a high BUN/creatinine ratio in this group, which has been demonstrated to be among the strongest predictors of mortality in acute heart failure [13] . Clearly, sodium homeostasis in this group is markedly altered.
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The current analysis further suggests that when hyponatremia is corrected by decongestive treatment, clinical outcome is better compared to patients with persistent hyponatremia, but still worse compared to patients without hyponatremia development.
There are several potential explanations for this observation. First, arterial blood pressure and baseline neurohumoral activation suggested that patients with disappearing hyponatremia might have had less advanced heart failure compared to patients with persistent, but more advanced than patients with no hyponatremia. This argument is further reinforced by the results of Lee et al. who found that disappearing hyponatremia in acute heart failure was associated with adverse outcome, but the effect was no longer significant when corrected for markers of disease severity [7] . Intriguingly in the current analysis however, patients with decompensation hyponatremia disappearing with decongestive treatment also demonstrated no increase in neurohumoral activation during admission and showed preserved diuretic efficacy similar to patients without hyponatremia. Despite these seemingly favorable characteristics, decongestion achieved was poor, both assessed by natriuretic peptide level changes and invasively measured central venous pressure. The reason for this observation remains unclear, but it might well be that clinicians were reluctant to pursue thorough decongestion in patients perceived to be at high risk because of initial presentation with hyponatremia, further encouraged by subsequent correction of the latter. In addition, despite the fact that patients with reversible decompensation hyponatremia had the longest in-hospital stay, the cumulative dose of diuretics used in this group was relatively low, similar to patients without hyponatremia, further suggesting that decongestive treatment might not have been aggressive enough in this group. This M A N U S C R I P T
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reinforces the widely accepted view that complete decongestion should be pursued in every heart failure patient to prevent readmissions [14] .
Arguably the most important finding of the current analysis was that treatment-induced hyponatremia was associated with a significantly elevated risk of death or heart failure readmission. At baseline, serum BUN levels, plasma renin activity and plasma aldosterone suggested no significantly increased neurohumoral activation in this group. Furthermore, plasma NT-proBNP levels as a surrogate for disease severity were also similar in this group compared to patients without hyponatremia development.
Moreover, it was clearly shown that patients with treatment-induced hyponatremia achieved adequate decongestion. What was strikingly different however between both groups was the amount of neurohumoral activation during decongestive treatment and the poor diuretic efficacy of patients with treatment-induced hyponatremia, findings suggesting that decongestive treatment was overly aggressive in this group. Indeed, it has been shown that the natriuretic response to diuretic treatment diminishes with progressive decongestion [15] . These results support a paradigm shift in the treatment of acute heart failure, as not only achieving effective decongestion, but also the way to achieve it (i.e., with more or less neurohumoral activation) might be important to improve clinical outcome.
Study limitations
The current analysis should be interpreted in the light of some study limitations.
First, this was a post-hoc analysis and therefore results should be considered M A N U S C R I P T
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14 exploratory and hypothesis-generating. Second, because of the different study designs of the ESCAPE and DOSE AHF study, some data were uniquely available in only one study population. Specifically, plasma NT-proBNP, plasma renin activity and plasma aldosterone were available for DOSE AHF but not ESCAPE patients, while invasive hemodynamic data were available only for the 172 ESCAPE patients included in the pulmonary artery catheter arm. In addition, the study population characteristics of both trials were also different, with ESCAPE including advanced heart failure patients with reduced ejection fraction in contrast to DOSE AHF, which included both patients with reduced and preserved ejection fraction. However, data from both studies were complimentary and findings were congruent. Third, in a minority of cases, discharge serum sodium levels were missing and the last observation was carried forward (mainly from day 5 or 7 after decongestive therapy). However, sensitivity analysis without these cases did not alter the study results. M A N U S C R I P T 
